If you have been reading about glucagon receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-04. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
== Classification == This enzyme has a classification number of EC 1.1.1.30. The first digit means that this enzyme is an oxidoreductase which means the purpose is to catalyze oxidation and reduction reaction pathways. The following two 1s indicate the subclass and sub-sub of the enzyme. In this case, 1.1.1 means this enzyme is an oxidoreductase that acts on the CH-OH group of the donor molecule using NAD(+) or NADP(+) as the acceptor. The 4th number, or 30 in this case, is the serial number of the enzyme to define it within its sub-subclass. 3-Hydroxybutryate dehydrogenase is also known as beta-hydroxybutyric dehydrogenase and is abbreviated BHBDH. Other common synonyms are shown below. The systematic name of this enzyme class is (R)-3-hydroxybutanoate:NAD+ oxidoreductase. Other names in common use include:
Schleswig-Holstein () is a coastal state that is the northernmost of the sixteen states of Germany, comprising most of the historical Duchy of Holstein and the southern part of the former Duchy of Schleswig. It borders Denmark, Mecklenburg-Vorpommern, Lower Saxony and the city-state of Hamburg. Its capital city is Kiel; other notable cities are Lübeck and Flensburg. It covers an area of 15,763 km2 (6,086 sq mi), making it the 5th smallest German state by area (including the city-states). Historically, the name can also refer to a larger region, containing both present-day Schleswig-Holstein and the former South Jutland County (Northern Schleswig; now part of the Region of Southern Denmark) in Denmark. Schleswig, known as South Jutland at the time, had been under Danish control since the fifth century. In the 12th century, however, it became a duchy within Denmark due to infighting in the Danish royal house. It bordered Holstein, which was a part of the Holy Roman Empire. Beginning in 1460, the King of Denmark ruled both Schleswig and Holstein as their duke. Schleswig was still part of Denmark, while Holstein remained part of the Holy Roman Empire. In the 19th century, both Danes and Germans believed they had a rightful claim to Schleswig-Holstein. While the population of Holstein and Lauenburg was entirely ethnically German, Schleswig had been predominantly Danish until the late 1700s and early 1800s, when extensive German influence led to the Germanization of South Schleswig.
=== "Active template" methodology === Leigh and co-workers recently began to explore a strategy in which template ions could also play an active role in promoting the crucial final covalent bond forming reaction that captures the interlocked structure (i.e., the metal has a dual function, acting as a template for entwining the precursors and catalyzing covalent bond formation between the reactants).
Sources: en.wikipedia.org
Even moderate sustained use of alcohol may increase anxiety and depression levels in some individuals. In most cases these drug induced psychiatric disorders fade away with prolonged abstinence. A protracted withdrawal syndrome can also occur with psychiatric and other symptoms persisting for months after cessation of use. Among the currently prevalent medications, benzodiazepines are the most notable drug for inducing prolonged withdrawal effects with symptoms sometimes persisting for years after cessation of use. Prospective epidemiological studies do not support the hypotheses that comorbidity of substance use disorders with other psychiatric illnesses is primarily a consequence of substance use or dependence or that increasing comorbidity is largely attributable to increasing use of substances. Yet emphasis is often on the effects of substances on the brain creating the impression that dual disorders are a natural consequence of these substances. However, addictive drugs or exposure to gambling will not lead to addictive behaviors or drug dependence in most individuals but only in vulnerable ones, although, according to some researchers, neuroadaptation or regulation of neuronal plasticity, and molecular changes, may alter gene expression in some cases and subsequently lead to substance use disorders. Research instruments are also often insufficiently sensitive to discriminate between independent, true dual pathology, and substance-induced symptoms.
=== Academic === In September 2023, the UNC School of Medicine opened Roper Hall on the former site of Berryhill Hall, built in 1970, which had served as the primary training site for medical students. The 172,000-square-foot facility is a training center with a 25,000-square-foot immersive simulation and visualization lab, a 400-seat active learning theater, and six floors of classrooms and meeting spaces. The building is named for Bill Roper, who served as CEO of UNC Health Care, dean of the UNC School of Medicine, and interim president of the University of North Carolina. Additional classrooms and administrative offices are located in Bondurant Hall on South Columbia Street, built in 2005 and named for Stuart Bondurant, who was dean of the School of Medicine from 1979 to 1994.
== External links == Equianalgesic Charts American Pain Society Guidelines Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain Online opioid equianalgesia calculator Electronic calculator that includes logic for bidirectional and dose-dependent conversions Shaheen, PE; Walsh, D; Lasheen, W; Davis, MP; Lagman, RL (2009). "Opioid equianalgesic tables: are they all equally dangerous?". J Pain Symptom Manage. 38 (3): 409–17. doi:10.1016/j.jpainsymman.2009.06.004. PMID 19735901.
Sources: en.wikipedia.org
In the CPC (centrifugal partition chromatography or hydrostatic countercurrent chromatography) instrument, the column consists of a series of cells interconnected by ducts attached to a rotor. This rotor rotates on its central axis creating the centrifugal field necessary to hold the stationary phase in place. The separation process in CPC is governed solely by the partitioning of solutes between the stationary and mobile phases, which mechanism can be easily described using the partition coefficients (KD) of solutes. CPC instruments are commercially available for laboratory, pilot, and industrial-scale separations with different sizes of columns ranging from some 10 milliliters to 10 liters in volume.
=== Fungal === A single fungal serpin has been characterized to date: celpin from Piromyces spp. strain E2. Piromyces is a genus of anaerobic fungi found in the gut of ruminants and is important for digesting plant material. Celpin is predicted to be inhibitory and contains two N-terminal dockerin domains in addition to its serpin domain. Dockerins are commonly found in proteins that localise to the fungal cellulosome, a large extracellular multiprotein complex that breaks down cellulose. It is therefore suggested that celpin may protect the cellulosome against plant proteases. Certain bacterial serpins similarly localize to the cellulosome.
This later on gave medical professionals grounds to support sterilization on the island. Furthermore, these factors resulted in immense and widespread poverty. Many Puerto Ricans faced perpetual hunger and growing unemployment rates. In 1930, the median family income was reported to be approx. $250 a year and "economically productive families" were attributing around 94% of their income toward acquiring food. Additionally, 27% of the labor force was unemployed. The current state of Puerto Rico confirmed the ideals Americans projected in the midst of the island's annexation about the longevity and potential of Puerto Rico. Puerto Ricans were once again viewed as ignorant and devious as they participated in "reckless breeding" in the midst of this economic downward spiral. This caused many Americans and a fraction of Puerto Ricans to believe that overpopulation essentially was the cause of the wide variety of problems on the island. Messages about Puerto Rico's increase in population began to spread rapidly by citizens, government officials, scientist, and industrial leaders/capitalist. In 1899, the population of Puerto Rico was less than a million and in 1917 was half of the population size that it would be four decades later. In the 1930s, Puerto Rico had a population growth rate of approximately 1.5%, while fertility rates were lower than developed and industrialized nations. According to Puerto Rico's planning report decades later, the island's population has grown from 687 people per square mile in 1960 to 793 in 1970.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.